Gilead Sciences' Truvada, or emtricitabine/TDF, together with safer sex practices was approved by the FDA for adolescents who are at risk of acquiring sexually transmitted HIV-1 infection. The drug was previously approved in 2012 as a pre-exposure prophylaxis in adults.
Sign up for ANA SmartBrief
Nursing news and information
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.